Zydus Life Science , a prominent player in the pharmaceutical industry, has announced the passing of Mr. Samir Desai, President-BU Biologics and a key member of the company's senior management. The company informed the stock exchanges BSE and NSE about this development on August 26, 2025.

Senior Management Change

Mr. Samir Desai, who held the position of President-BU Biologics at Zydus Lifesciences, passed away on August 26, 2025. As a result, he ceases to be part of the company's senior management team. The company expressed profound grief in its communication to the stock exchanges.

In compliance with Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, Zydus Lifesciences provided the necessary details regarding this change in senior management.

Enhanced ESG Rating Performance

Zydus Lifesciences has received an improved Environmental, Social, and Governance (ESG) score for the financial year 2024-2025. SES ESG Research Private Limited has assigned the company an ESG score of 69.4, representing an improvement from the previous year's score of 67.8.

According to the rating framework, a score ranging between 60-70 is categorized as Medium Risk. The company noted that this rating was unsolicited, indicating an independent assessment of its ESG practices.

Regulatory Compliance and Disclosure

Dhaval N. Soni, Company Secretary and Compliance Officer of Zydus Lifesciences, signed the communications to the stock exchanges. The ESG rating disclosure was made in compliance with Regulation 30 of the Listing Regulations, read with SEBI Circulars dated November 11, 2024, and December 31, 2024.

The company ensured timely disclosure of these significant events, maintaining transparency with its stakeholders and complying with regulatory requirements. While Zydus Lifesciences faces the challenge of losing a key member of its senior management team, the improved ESG score indicates the company's ongoing efforts to enhance its sustainability and governance practices.

Zydus Lifesciences announced that Sentyln Therapeutics has received FDA acceptance for the resubmission of its New Drug Application (NDA) for CUTX-101, intended to treat Menkes disease in pediatric patients. The FDA has assigned January 14, 2026 as the new PDUFA Target Action Date for the resubmission.

Regulatory Timeline and Acceptance Details

The FDA accepted the resubmission as a Class I response, marking a significant milestone in the approval process for CUTX-101. Sentyln resubmitted its revised NDA on November 14, 2025 after receiving a complete response letter (CRL) from the FDA on September 30, 2025.

Complete Response Letter Analysis

The CRL cited observations regarding the manufacturing sites cGMP compliance but did not identify any other approvability concerns. Importantly, the FDA found no deficiencies in CUTX-101's efficacy and safety data, which demonstrate improvement in overall survival for Menkes disease subjects who received early treatment with the therapy.

CUTX-101 Clinical Efficacy Data

CUTX-101 is an investigational copper histidinate candidate that showed statistically significant improvement in overall survival for Menkes disease subjects. The clinical trial results demonstrated an early 80.00% reduction in the risk of death compared to untreated historical controls.

Market Significance and Disease Impact

If approved, CUTX-101 will be the first and only FDA approved treatment available for Menkes disease, a rare X-linked recessive pediatric genetic disease. The condition impacts an estimated 1 in 34,810 to as high as 1 in 8,664 live male births and is characterized by distinctive clinical features including sparse and depigmented hair, connective tissue problems, and severe neurological symptoms.

This FDA acceptance brings the potential first treatment for Menkes disease closer to approval, offering hope for patients and families affected by this rare condition.